Q3 2024 |
93 |
$9.65B |
+$239M |
-$134M |
+$105M |
BGNE, INCY, ACAD, SMMT, MDGL
|
13F-HR |
11/14/2024, 04:07 PM |
Q2 2024 |
95 |
$7.83B |
+$925M |
-$626M |
+$300M |
INCY, BGNE, ACAD, MDGL, RVMD
|
13F-HR |
8/14/2024, 04:05 PM |
Q1 2024 |
87 |
$7.97B |
+$382M |
-$511M |
-$129M |
INCY, BGNE, ACAD, MDGL, RYTM
|
13F-HR |
5/15/2024, 04:37 PM |
Q4 2023 |
84 |
$8.79B |
+$625M |
-$10.3B |
-$9.69B |
INCY, BGNE, ACAD, MDGL, RYTM
|
13F-HR |
2/14/2024, 05:12 PM |
Q3 2023 |
101 |
$17.4B |
+$187M |
-$322M |
-$134M |
SGEN, BGNE, INCY, ACAD, BMRN
|
13F-HR |
11/14/2023, 04:25 PM |
Q2 2023 |
107 |
$17.3B |
+$437M |
-$522M |
-$85.6M |
SGEN, INCY, BGNE, ACAD, MDGL
|
13F-HR |
8/14/2023, 04:13 PM |
Q1 2023 |
105 |
$18.4B |
+$255M |
-$1.25B |
-$996M |
SGEN, INCY, BGNE, ACAD, MDGL
|
13F-HR |
5/15/2023, 04:04 PM |
Q4 2022 |
113 |
$16.7B |
+$272M |
-$571M |
-$298M |
SGEN, INCY, BGNE, BMRN, ACAD
|
13F-HR |
2/14/2023, 04:06 PM |
Q3 2022 |
115 |
$15.3B |
+$270M |
-$589M |
-$319M |
SGEN, INCY, BGNE, ACAD, BMRN
|
13F-HR |
11/14/2022, 04:06 PM |
Q2 2022 |
117 |
$17.6B |
+$252M |
-$199M |
+$53.1M |
SGEN, INCY, BGNE, BMRN, ACAD
|
13F-HR |
8/15/2022, 04:56 PM |
Q1 2022 |
118 |
$17.4B |
+$347M |
-$107M |
+$240M |
SGEN, INCY, BGNE, ACAD, BMRN
|
13F-HR |
5/16/2022, 04:05 PM |
Q4 2021 |
121 |
$20.6B |
+$386M |
-$191M |
+$195M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
2/14/2022, 04:09 PM |
Q3 2021 |
122 |
$22.8B |
+$594M |
-$307M |
+$287M |
SGEN, BGNE, INCY, KOD, ASND
|
13F-HR |
11/15/2021, 03:58 PM |
Q2 2021 |
120 |
$22.8B |
+$488M |
-$972M |
-$485M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
8/16/2021, 04:11 PM |
Q1 2021 |
126 |
$23.1B |
+$741M |
-$871M |
-$130M |
SGEN, BGNE, INCY, KOD, ACAD
|
13F-HR |
5/17/2021, 04:03 PM |
Q4 2020 |
126 |
$26.5B |
+$1.16B |
-$1.25B |
-$95.5M |
SGEN, BGNE, INCY, ACAD, KOD
|
13F-HR |
2/16/2021, 03:59 PM |
Q3 2020 |
120 |
$25B |
+$10.4B |
-$8.32B |
+$2.08B |
SGEN, BGNE, INCY, ACAD, ALXN
|
13F-HR |
11/16/2020, 04:00 PM |
Q2 2020 |
114 |
$22.7B |
+$622M |
-$796M |
-$174M |
SGEN, INCY, BGNE, ACAD, ALXN
|
13F-HR |
8/14/2020, 04:08 PM |
Q1 2020 |
110 |
$16.2B |
+$318M |
-$145M |
+$174M |
SGEN, INCY, ACAD, BGNE, ALXN
|
13F-HR |
5/15/2020, 04:03 PM |
Q4 2019 |
99 |
$18.8B |
+$689M |
-$1.12B |
-$433M |
SGEN, INCY, BGNE, ACAD, ALXN
|
13F-HR |
2/14/2020, 04:26 PM |
Q3 2019 |
109 |
$14.7B |
+$343M |
-$273M |
+$70M |
SGEN, INCY, ACAD, BGNE, ALXN
|
13F-HR |
11/14/2019, 04:05 PM |
Q2 2019 |
103 |
$14.7B |
+$308M |
-$653M |
-$345M |
SGEN, INCY, BGNE, ALXN, ACAD
|
13F-HR |
8/14/2019, 04:01 PM |
Q1 2019 |
96 |
$15.6B |
+$258M |
-$245M |
+$12.7M |
SGEN, INCY, BGNE, ALXN, ACAD
|
13F-HR |
5/15/2019, 04:06 PM |
Q4 2018 |
93 |
$12.2B |
+$526M |
-$492M |
+$33.9M |
SGEN, INCY, BGNE, ALXN, GHDX
|
13F-HR |
2/13/2019, 04:14 PM |
Q3 2018 |
97 |
$15.2B |
+$453M |
-$605M |
-$152M |
SGEN, INCY, BGNE, ALXN, GHDX
|
13F-HR |
11/14/2018, 03:50 PM |
Q2 2018 |
119 |
$13.3B |
+$1.49B |
-$474M |
+$1.02B |
SGEN, INCY, BGNE, ALXN, BMRN
|
13F-HR |
8/14/2018, 03:48 PM |
Q1 2018 |
114 |
$11.8B |
+$818M |
-$325M |
+$493M |
INCY, SGEN, BGNE, ALXN, BMRN
|
13F-HR |
5/15/2018, 03:47 PM |
Q4 2017 |
123 |
$11.5B |
+$716M |
-$306M |
+$410M |
INCY, SGEN, ALXN, ACAD, BMRN
|
13F-HR |
2/14/2018, 03:49 PM |
Q3 2017 |
121 |
$12.3B |
+$271M |
-$98.4M |
+$173M |
INCY, SGEN, ALXN, ACAD, BMRN
|
13F-HR |
11/14/2017, 03:45 PM |
Q2 2017 |
120 |
$11.4B |
+$420M |
-$238M |
+$182M |
INCY, SGEN, ALXN, ACAD, BMRN
|
13F-HR |
8/14/2017, 03:48 PM |
Q1 2017 |
119 |
$12.2B |
+$1.55B |
-$1.27B |
+$286M |
INCY, SGEN, ACAD, ALXN, GHDX
|
13F-HR |
5/15/2017, 04:00 PM |
Q4 2016 |
133 |
$10.2B |
+$302M |
-$1.03B |
-$728M |
SGEN, INCY, ALXN, ACAD, GHDX
|
13F-HR |
2/14/2017, 04:13 PM |
Q3 2016 |
134 |
$11B |
+$268M |
-$281M |
-$12.2M |
SGEN, INCY, ABBV, ACAD, ALXN
|
13F-HR |
11/14/2016, 05:30 PM |
Q2 2016 |
135 |
$9.54B |
+$85M |
-$544M |
-$459M |
INCY, SGEN, ABBV, ACAD, ALXN
|
13F-HR |
8/15/2016, 04:07 PM |
Q1 2016 |
134 |
$9.48B |
+$970M |
-$380M |
+$590M |
INCY, SGEN, ALXN, ABBV, ACAD
|
13F-HR |
5/16/2016, 04:12 PM |
Q4 2015 |
133 |
$12.1B |
+$479M |
-$140M |
+$340M |
INCY, SGEN, ALXN, ABBV, ACAD
|
13F-HR |
2/16/2016, 04:52 PM |
Q3 2015 |
133 |
$10.8B |
+$1.45B |
-$710M |
+$737M |
INCY, SGEN, ALXN, ABBV, ACAD
|
13F-HR |
11/16/2015, 04:07 PM |
Q2 2015 |
126 |
$11.4B |
+$2.52B |
-$4.42B |
-$1.91B |
INCY, SGEN, ALXN, ABBV, ACAD
|
13F-HR |
8/14/2015, 04:19 PM |
Q1 2015 |
130 |
$12B |
+$633M |
-$871M |
-$238M |
PCYC, INCY, GEVA, SGEN, ACAD
|
13F-HR |
5/15/2015, 04:06 PM |
Q4 2014 |
121 |
$9.8B |
+$882M |
-$134M |
+$748M |
PCYC, INCY, GEVA, SGEN, AVNR
|
13F-HR |
2/17/2015, 04:15 PM |
Q3 2014 |
107 |
$7.83B |
+$270M |
-$532M |
-$262M |
PCYC, SGEN, GEVA, INCY, ACAD
|
13F-HR |
11/14/2014, 04:51 PM |
Q2 2014 |
106 |
$8.16B |
+$449M |
-$373M |
+$75.6M |
GEVA, PCYC, SGEN, INCY, ACAD
|
13F-HR |
8/14/2014, 04:15 PM |
Q1 2014 |
108 |
$7.87B |
+$656M |
-$435M |
+$222M |
SGEN, GEVA, PCYC, INCY, ACAD
|
13F-HR |
5/15/2014, 04:10 PM |
Q4 2013 |
95 |
$7.1B |
$0 |
$0 |
|
PCYC, SGEN, INCY, GEVA, ACAD
|
13F-HR |
2/14/2014, 04:21 PM |